BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen M, Elens L, Johnson-davis KL, Kunicki PK, Macphee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring 2019;41:261-307. [DOI: 10.1097/ftd.0000000000000640] [Cited by in Crossref: 131] [Cited by in F6Publishing: 46] [Article Influence: 43.7] [Reference Citation Analysis]
Number Citing Articles
1 Bonneville E, Gautier-Veyret E, Ihl C, Hilleret MN, Baudrant M, Fonrose X, Stanke-Labesque F. Unexpected overdose blood concentration of tacrolimus: Keep in mind the role of inflammation. Br J Clin Pharmacol 2020;86:1888-91. [PMID: 32199027 DOI: 10.1111/bcp.14292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 van Gelder T, Vinks AA. Machine Learning as a Novel Method to Support Therapeutic Drug Management and Precision Dosing. Clin Pharmacol Ther 2021;110:273-6. [PMID: 34311506 DOI: 10.1002/cpt.2326] [Reference Citation Analysis]
3 Martuszewski A, Paluszkiewicz P, Król M, Banasik M, Kepinska M. Donor-Derived Cell-Free DNA in Kidney Transplantation as a Potential Rejection Biomarker: A Systematic Literature Review. J Clin Med 2021;10:E193. [PMID: 33430458 DOI: 10.3390/jcm10020193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pinon M, De Nicolò A, Pizzol A, Antonucci M, D'Avolio A, Serpe L, Dell'Olio D, Catalano S, Tandoi F, Romagnoli R, Canaparo R, Calvo PL. Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients. Sci Rep 2021;11:443. [PMID: 33432012 DOI: 10.1038/s41598-020-79574-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Sikma MA, Hunault CC, Van Maarseveen EM, Huitema ADR, Van de Graaf EA, Kirkels JH, Verhaar MC, Grutters JC, Kesecioglu J, De Lange DW. High Variability of Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation. Eur J Drug Metab Pharmacokinet 2020;45:123-34. [PMID: 31745812 DOI: 10.1007/s13318-019-00591-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Wang J, Huang L, Gao P, Hu Y, Ni Y, Zhu Z, Zhang L, Yang J, Zhang H, Fang L. Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms. Eur J Clin Pharmacol 2021;77:71-7. [PMID: 32803289 DOI: 10.1007/s00228-020-02977-y] [Reference Citation Analysis]
7 Bunthof KLW, Al-Hassany L, Nakshbandi G, Hesselink DA, van Schaik RHN, Ten Dam MAGJ, Baas MC, Hilbrands LB, van Gelder T. A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients. Clin Transl Sci 2021. [PMID: 34905302 DOI: 10.1111/cts.13206] [Reference Citation Analysis]
8 Warzyszyńska K, Zawistowski M, Karpeta E, Jałbrzykowska A, Kosieradzki M. Renal Cyp3a5-Expressing Genotype Decreases Tacrolimus-to-Dose Ratio in Small Cohort of Renal Transplant Recipients—Preliminary Report. Transplantation Proceedings 2022. [DOI: 10.1016/j.transproceed.2022.02.018] [Reference Citation Analysis]
9 Aral AM, Zamora R, Barclay D, Yin J, El-Dehaibi F, Erbas VE, Dong L, Zhang Z, Sahin H, Gorantla VS, Vodovotz Y. The Effects of Tacrolimus on Tissue-Specific, Protein-Level Inflammatory Networks in Vascularized Composite Allotransplantation. Front Immunol 2021;12:591154. [PMID: 34017323 DOI: 10.3389/fimmu.2021.591154] [Reference Citation Analysis]
10 Lantigua D, Trimper J, Unal B, Camci-Unal G. A new paper-based biosensor for therapeutic drug monitoring. Lab Chip 2021;21:3289-97. [PMID: 34612459 DOI: 10.1039/d1lc00473e] [Reference Citation Analysis]
11 Bayne J, Francke M, Ma E, Rubin GA, Avula UMR, Baksh H, Givens R, Wan EY. Increased Incidence of Chronic Kidney Injury in African Americans Following Cardiac Transplantation. J Racial Ethn Health Disparities 2020. [PMID: 33113077 DOI: 10.1007/s40615-020-00906-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Undre N, Hussain I, Meijer J, Stanta J, Swan G, Dawson I. Quantitation of Tacrolimus in Human Whole Blood Samples Using the MITRA Microsampling Device. Ther Drug Monit 2021;43:364-70. [PMID: 33149056 DOI: 10.1097/FTD.0000000000000833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Wu L, Ye Z, Zhang X, Zheng A, Zhang X, Chen L, Ouyang D, Zheng L, Liu X. Development and evaluation of a new test kit for determination of immunosuppressants in blood by UHPLC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis 2022. [DOI: 10.1016/j.jpba.2022.114756] [Reference Citation Analysis]
14 Budde K, Halleck F. Risks and benefits of everolimus. Transpl Int 2019;32:1124-6. [PMID: 31397931 DOI: 10.1111/tri.13489] [Reference Citation Analysis]
15 De Nicolò A, Pinon M, Palermiti A, Nonnato A, Manca A, Mula J, Catalano S, Tandoi F, Romagnoli R, D'Avolio A, Calvo PL. Monitoring Tacrolimus Concentrations in Whole Blood and Peripheral Blood Mononuclear Cells: Inter- and Intra-Patient Variability in a Cohort of Pediatric Patients. Front Pharmacol 2021;12:750433. [PMID: 34803692 DOI: 10.3389/fphar.2021.750433] [Reference Citation Analysis]
16 Du Y, Song W, Xiong XF, Ge WH, Huai-Jun Z. Population pharmacokinetics and dosage optimization of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients. Xenobiotica 2022;:1-33. [PMID: 35502774 DOI: 10.1080/00498254.2022.2073851] [Reference Citation Analysis]
17 Nakamura T, Fukuda M, Matsukane R, Suetsugu K, Harada N, Yoshizumi T, Egashira N, Mori M, Masuda S. Influence of POR*28 Polymorphisms on CYP3A5*3-Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation. Int J Mol Sci 2020;21:E2287. [PMID: 32225074 DOI: 10.3390/ijms21072287] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Veenhof H, van Boven JFM, van der Voort A, Berger SP, Bakker SJL, Touw DJ. Effects, costs and implementation of monitoring kidney transplant patients' tacrolimus levels with dried blood spot sampling: A randomized controlled hybrid implementation trial. Br J Clin Pharmacol 2020;86:1357-66. [PMID: 32077134 DOI: 10.1111/bcp.14249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Braithwaite HE, Darley DR, Brett J, Day RO, Carland JE. Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: A systematic review. Transplant Rev (Orlando) 2021;35:100610. [PMID: 33756310 DOI: 10.1016/j.trre.2021.100610] [Reference Citation Analysis]
20 Bodnar-Broniarczyk M, Durlik M, Bączkowska T, Czerwińska K, Marszałek R, Pawiński T. Kidney and Liver Tissue Tacrolimus Concentrations in Adult Transplant Recipients-The Influence of the Whole Blood and Tissue Concentrations on Efficiency of Treatment during Immunosuppressive Therapy. Pharmaceutics 2021;13:1576. [PMID: 34683869 DOI: 10.3390/pharmaceutics13101576] [Reference Citation Analysis]
21 Faravardeh A, Akkina S, Villicana R, Guerra G, Moten MA, Meier-Kriesche U, Stevens DR, Patel SJ, Bunnapradist S. Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial. Ann Transplant 2021;26:e929535. [PMID: 33859155 DOI: 10.12659/AOT.929535] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Franken LG, Francke MI, Andrews LM, van Schaik RHN, Li Y, de Wit LEA, Baan CC, Hesselink DA, de Winter BCM. A Population Pharmacokinetic Model of Whole-Blood and Intracellular Tacrolimus in Kidney Transplant Recipients. Eur J Drug Metab Pharmacokinet 2022. [PMID: 35442010 DOI: 10.1007/s13318-022-00767-8] [Reference Citation Analysis]
23 Wang R, Wang W, Ma K, Duan X, Wang F, Huang M, Zhang W, Liang T. Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study. Front Pharmacol 2020;11:1252. [PMID: 32973503 DOI: 10.3389/fphar.2020.01252] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Susan Mathew B, Mathew SK, Winston Aruldhas B, Prabha R, Gangadharan N, George David V, Varughese S, Tharayil John G. Analytical and clinical validation of Dried blood spot and Volumetric Absorptive Microsampling for measurement of tacrolimus and creatinine after renal transplantation. Clin Biochem 2022:S0009-9120(22)00117-5. [PMID: 35490728 DOI: 10.1016/j.clinbiochem.2022.04.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Chavant A, Fonrose X, Gautier-Veyret E, Hilleret MN, Roustit M, Stanke-Labesque F. Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation? Pharmaceutics 2021;13:1960. [PMID: 34834375 DOI: 10.3390/pharmaceutics13111960] [Reference Citation Analysis]
26 Willigenburg HV, Domburg BV, Ambagtsheer G, Brandt RM, Hesselink DA, de Bruin RW, de Winter BC. Validation of a dried blood spot method to measure tacrolimus concentrations in small volumes of mouse blood. Bioanalysis 2022. [PMID: 35289217 DOI: 10.4155/bio-2021-0247] [Reference Citation Analysis]
27 Jia JJ, Zhang SY, Yu J, Xie HY, Zhou L, Zheng SS. The immune profiles and "minimizing tacrolimus" strategy for long-term survival recipients after liver transplantation. Hepatobiliary Pancreat Dis Int 2021;20:190-2. [PMID: 32859505 DOI: 10.1016/j.hbpd.2020.08.004] [Reference Citation Analysis]
28 Cai X, Song H, Jiao Z, Yang H, Zhu M, Wang C, Wei D, Shi L, Wu B, Chen J. Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients. Eur J Pharm Sci 2020;152:105448. [PMID: 32621968 DOI: 10.1016/j.ejps.2020.105448] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Ky TQ, Silas NP, Taylor RM, Barakat AO, Harb R, Laviste NC, Park JM. Evaluation of a Standardized Tacrolimus Therapeutic Drug Monitoring Protocol in Stable Kidney Transplant Recipients. Prog Transplant 2022;:15269248221107043. [PMID: 35695240 DOI: 10.1177/15269248221107043] [Reference Citation Analysis]
30 Yoshikawa N, Takeshima H, Sekine M, Akizuki K, Hidaka T, Shimoda K, Ikeda R. Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion. Pharmaceuticals (Basel) 2021;14:353. [PMID: 33920149 DOI: 10.3390/ph14040353] [Reference Citation Analysis]
31 van Eerden RAG, Oomen-de Hoop E, Noordam A, Mathijssen RHJ, Koolen SLW. Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors. Pharmaceuticals (Basel) 2021;14:119. [PMID: 33557114 DOI: 10.3390/ph14020119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Pan F, Cao S, Li XL, Jia YN, Wang RL, He Q, Zhu JQ. The Model for End-Stage Liver Disease Score and the Follow-Up Period Can Cause the Shift of Circulating Lymphocyte Subsets in Liver Transplant Recipients. Front Med (Lausanne) 2021;8:779443. [PMID: 35047528 DOI: 10.3389/fmed.2021.779443] [Reference Citation Analysis]
33 Dong Y, Xu Q, Li R, Tao Y, Zhang Q, Li J, Ma Z, Shen C, Zhong M, Wang Z, Qiu X. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation. Gene 2022;809:146007. [PMID: 34688813 DOI: 10.1016/j.gene.2021.146007] [Reference Citation Analysis]
34 Kindem IA, Bjerre A, Åsberg A, Midtvedt K, Bergan S, Vethe NT. Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients-A Cross-Validation Study. Ther Drug Monit 2021;43:371-5. [PMID: 33596033 DOI: 10.1097/FTD.0000000000000873] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Leino AD, Pai MP. Maintenance Immunosuppression in Solid Organ Transplantation: Integrating Novel Pharmacodynamic Biomarkers to Inform Calcineurin Inhibitor Dose Selection. Clin Pharmacokinet 2020;59:1317-34. [PMID: 32720300 DOI: 10.1007/s40262-020-00923-w] [Reference Citation Analysis]
36 Gelder TV, Etsouli O, Moes DJ, Swen JJ. Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations. Genes (Basel) 2020;11:E1205. [PMID: 33076474 DOI: 10.3390/genes11101205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Lemaitre F, Monchaud C, Woillard JB, Picard N, Marquet P. [Summary of the recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) on the therapeutic drug monitoring of tacrolimus]. Therapie 2020;75:681-5. [PMID: 32653093 DOI: 10.1016/j.therap.2020.06.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Prado-Velasco M, Borobia A, Carcas-Sansuan A. Predictive engines based on pharmacokinetics modelling for tacrolimus personalized dosage in paediatric renal transplant patients. Sci Rep 2020;10:7542. [PMID: 32371893 DOI: 10.1038/s41598-020-64189-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
39 Balevic SJ, Sagcal-Gironella ACP. Precision Medicine: Towards Individualized Dosing in Pediatric Rheumatology. Rheum Dis Clin North Am 2022;48:305-30. [PMID: 34798954 DOI: 10.1016/j.rdc.2021.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Zhang M, Tajima S, Shigematsu T, Fu R, Noguchi H, Kaku K, Tsuchimoto A, Okabe Y, Egashira N, Masuda S. Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients. Int J Mol Sci 2020;21:E2976. [PMID: 32340188 DOI: 10.3390/ijms21082976] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Kim JM, Ryu JH, Lee KW, Hong SK, Yang K, Choi GS, Kim YA, Lee JY, Yi NJ, Kwon CHD, Chu CW, Suh KS, Joh JW. Effect of CYP3A5 on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients. J Clin Med 2020;9:E2897. [PMID: 32911703 DOI: 10.3390/jcm9092897] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Santulario Verdú L, García-romero E, Díez-lópez C. Impacto clínico de la variabilidad en la concentración sanguínea de inhibidores de calcineurina en trasplante cardiaco: una espada de doble filo. Revista Española de Cardiología 2022;75:112-4. [DOI: 10.1016/j.recesp.2021.08.019] [Reference Citation Analysis]
43 Bodnar-broniarczyk M, Warzyszyńska K, Czerwińska K, Marszałek D, Dziewa N, Kosieradzki M, Pawiński T. Development and Validation of the New Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Unbound Tacrolimus in the Plasma Ultrafiltrate of Transplant Recipients. Pharmaceutics 2022;14:632. [DOI: 10.3390/pharmaceutics14030632] [Reference Citation Analysis]
44 Boosman RJ, Burgers JA, Smit EF, Steeghs N, van der Wekken AJ, Beijnen JH, Huitema ADR, Ter Heine R. Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer. Drugs 2021. [PMID: 34894338 DOI: 10.1007/s40265-021-01654-3] [Reference Citation Analysis]
45 Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri SR, Bathini T, Pivovarova A, Smith JR, Cheungpasitporn W. Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients. J Clin Med 2020;9:E2193. [PMID: 32664531 DOI: 10.3390/jcm9072193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
46 Huang L, Wang J, Yang J, Zhang H, Hu Y, Miao J, Mao J, Fang L. Impact of Sampling Time Variability on Tacrolimus Dosage Regimen in Pediatric Primary Nephrotic Syndrome: Single-Center, Prospective, Observational Study. Front Pharmacol 2021;12:726667. [PMID: 35069185 DOI: 10.3389/fphar.2021.726667] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Zheng P, Yu Z, Li L, Liu S, Lou Y, Hao X, Yu P, Lei M, Qi Q, Wang Z, Gao F, Zhang Y, Li Y. Predicting Blood Concentration of Tacrolimus in Patients With Autoimmune Diseases Using Machine Learning Techniques Based on Real-World Evidence. Front Pharmacol 2021;12:727245. [PMID: 34630104 DOI: 10.3389/fphar.2021.727245] [Reference Citation Analysis]
48 Sikma MA, Hunault CC, Huitema ADR, De Lange DW, Van Maarseveen EM. Clinical Pharmacokinetics and Impact of Hematocrit on Monitoring and Dosing of Tacrolimus Early After Heart and Lung Transplantation. Clin Pharmacokinet 2020;59:403-8. [PMID: 31820394 DOI: 10.1007/s40262-019-00846-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
49 Phan M, Chavan R, Beuttler R, Benipayo N, Magedman G, Buchbinder D, Tomaszewski D, Yang S. Evaluating risk factors for acute graft versus host disease in pediatric hematopoietic stem cell transplant patients receiving tacrolimus. Clin Transl Sci 2021;14:1303-13. [PMID: 33503293 DOI: 10.1111/cts.12982] [Reference Citation Analysis]
50 Srinivas L, Gracious N, Nair RR. Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients. Front Pharmacol 2021;12:726784. [PMID: 34916931 DOI: 10.3389/fphar.2021.726784] [Reference Citation Analysis]
51 Alghanem SS, Soliman MM, Alibrahim AA, Gheith O, Kenawy AS, Awad A. Monitoring Tacrolimus Trough Concentrations During the First Year After Kidney Transplantation: A National Retrospective Cohort Study. Front Pharmacol 2020;11:566638. [PMID: 33658922 DOI: 10.3389/fphar.2020.566638] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Zhu J, Campagne O, Torrice CD, Flynn G, Miller JA, Patel T, Suzuki O, Ptachcinski JR, Armistead PM, Wiltshire T, Mager DE, Weiner DL, Crona DJ. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients. Clin Transl Sci 2021;14:908-18. [PMID: 33502111 DOI: 10.1111/cts.12956] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Francke MI, Hesselink DA, Li Y, Koch BCP, de Wit LEA, van Schaik RHN, Yang L, Baan CC, van Gelder T, de Winter BCM. Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients. Br J Clin Pharmacol 2021;87:1918-29. [PMID: 33025649 DOI: 10.1111/bcp.14585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Zhang Q, Tian X, Chen G, Yu Z, Zhang X, Lu J, Zhang J, Wang P, Hao X, Huang Y, Wang Z, Gao F, Yang J. A Prediction Model for Tacrolimus Daily Dose in Kidney Transplant Recipients With Machine Learning and Deep Learning Techniques. Front Med (Lausanne) 2022;9:813117. [PMID: 35712101 DOI: 10.3389/fmed.2022.813117] [Reference Citation Analysis]
55 Udomkarnjananun S, Francke MI, De Winter BCM, Mulder MB, Baan CC, Metselaar HJ, den Hoed CM, Hesselink DA. Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. Best Pract Res Clin Gastroenterol 2021;54-55:101756. [PMID: 34874840 DOI: 10.1016/j.bpg.2021.101756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Henin E, Govoni M, Cella M, Laveille C, Piotti G. Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations. Adv Ther 2021;38:5317-32. [PMID: 34515977 DOI: 10.1007/s12325-021-01905-5] [Reference Citation Analysis]
57 Li C, Lu J, Zhou S, Wei Y, Lv C, Liu T, Wu Y, Wu D, Qi J, Cai R. Influential Factors and Efficacy Analysis of Tacrolimus Concentration After Allogeneic Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major. Pharmgenomics Pers Med 2021;14:1221-37. [PMID: 34594128 DOI: 10.2147/PGPM.S325103] [Reference Citation Analysis]
58 Francke MI, Andrews LM, Le HL, van de Wetering J, Clahsen-van Groningen MC, van Gelder T, van Schaik RHN, van der Holt B, de Winter BCM, Hesselink DA. Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial. Clin Pharmacol Ther 2021;110:169-78. [PMID: 33452682 DOI: 10.1002/cpt.2163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Schmulenson E, Zimmermann N, Mikus G, Joerger M, Jaehde U. Current status and future outlooks on therapeutic drug monitoring of fluorouracil. Expert Opin Drug Metab Toxicol 2022. [PMID: 35029518 DOI: 10.1080/17425255.2021.2029403] [Reference Citation Analysis]
60 van der Zwan M, Hesselink DA, van den Hoogen MWF, Baan CC. Costimulation Blockade in Kidney Transplant Recipients. Drugs 2020;80:33-46. [PMID: 31749062 DOI: 10.1007/s40265-019-01226-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
61 Yang N, Du Y, He J, Ge J, Wang M, Sun R, Zhu H, Ge W. Distribution evaluation of tacrolimus in the ascitic fluid of liver transplant recipients with liver cirrhosis by a sensitive ultra-performance liquid chromatography-tandem mass spectrometry method. J Sep Sci 2021. [PMID: 34694679 DOI: 10.1002/jssc.202100714] [Reference Citation Analysis]
62 Tron C, Woillard JB, Houssel-Debry P, David V, Jezequel C, Rayar M, Balakirouchenane D, Blanchet B, Debord J, Petitcollin A, Roussel M, Verdier MC, Bellissant E, Lemaitre F. Pharmacogenetic-Whole blood and intracellular pharmacokinetic-Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients. PLoS One 2020;15:e0230195. [PMID: 32163483 DOI: 10.1371/journal.pone.0230195] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
63 Grujičić M, Žigić M, Maksić M, Hajder S, Golić D, Gašić B, Rakanović D, Vasić N, Laganin N, Roljić Z, Stajčić L, Mišković M, Mićić-zrnić D, Topić G, Đajić V. Results of the kidney transplant programme at the University Clinical Centre of the Republic of Srpska from 2010 to 2018. Scripta Medica 2019;50:82-8. [DOI: 10.5937/scriptamed50-22278] [Reference Citation Analysis]
64 Quinlan C. The Future of Paediatric Nephrology—Genomics and Personalised Precision Medicine. Curr Pediatr Rep 2020;8:115-21. [DOI: 10.1007/s40124-020-00218-5] [Reference Citation Analysis]
65 Bietenbeck A, Streichert T. Preparing Laboratories for Interconnected Health Care. Diagnostics (Basel) 2021;11:1487. [PMID: 34441421 DOI: 10.3390/diagnostics11081487] [Reference Citation Analysis]
66 Liu M, Shaver CM, Birdwell KA, Heeney SA, Shaffer CM, Van Driest SL. Composite CYP3A phenotypes influence tacrolimus dose-adjusted concentration in lung transplant recipients. Pharmacogenet Genomics 2022. [PMID: 35389944 DOI: 10.1097/FPC.0000000000000472] [Reference Citation Analysis]
67 Jin B, Kim GY, Cheon SM. Tacrolimus-induced neurotoxicity from bipolar disorder to status epilepticus under the therapeutic serum level: a case report. BMC Neurol 2021;21:448. [PMID: 34781882 DOI: 10.1186/s12883-021-02479-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Fu Q, Jing Y, Liu Mr G, Jiang Mr X, Liu H, Kong Y, Hou X, Cao L, Deng P, Xiao P, Xiao J, Peng H, Wei X. Machine learning-based method for tacrolimus dose predictions in Chinese kidney transplant perioperative patients. J Clin Pharm Ther 2021. [PMID: 34802160 DOI: 10.1111/jcpt.13579] [Reference Citation Analysis]
69 Gustavsen MT, Midtvedt K, Robertsen I, Woillard JB, Debord J, Klaasen RA, Vethe NT, Bergan S, Åsberg A. Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients. Clin Transl Sci 2020;13:1327-35. [PMID: 32652886 DOI: 10.1111/cts.12833] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
70 Everton JBF, Patrício FJB, Faria MS, Ferreira TCA, Romao EA, Silva GEB, Magalhães M. CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients. Eur J Clin Pharmacol 2021;77:879-86. [PMID: 33398393 DOI: 10.1007/s00228-020-03076-8] [Reference Citation Analysis]
71 Wu Y, Fang F, Wang Z, Wen P, Fan J. The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation. Eur J Clin Pharmacol 2021;77:859-67. [PMID: 33386894 DOI: 10.1007/s00228-020-03058-w] [Reference Citation Analysis]
72 Stefanović N, Veličković-Radovanović R, Danković K, Pavlović I, Catić-Đorđević A, Bašić J, Despotović M, Jevtović-Stoimenov T, Mitić B, Cvetković T. Effect of the Interrelation between CYP3A5 Genotype, Concentration/Dose Ratio and Intrapatient Variability of Tacrolimus on Kidney Graft Function: Monte Carlo Simulation Approach. Pharmaceutics 2021;13:1970. [PMID: 34834385 DOI: 10.3390/pharmaceutics13111970] [Reference Citation Analysis]
73 Andrews LM, de Winter BCM, Cornelissen EAM, de Jong H, Hesselink DA, Schreuder MF, Brüggemann RJM, van Gelder T, Cransberg K. A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement. Clin Pharmacokinet 2020;59:591-603. [PMID: 31654367 DOI: 10.1007/s40262-019-00831-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Kirubakaran R, Hennig S, Maslen B, Day RO, Carland JE, Stocker SL. Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients. Br J Clin Pharmacol 2021. [PMID: 34558092 DOI: 10.1111/bcp.15091] [Reference Citation Analysis]
75 Lo Re F, Angelini J, Sponga S, Nalli C, Zucchetto A, Biasizzo J, Livi U, Baraldo M. Therapeutic Drug Monitoring of Mycophenolic Acid as a Precision Medicine Tool for Heart Transplant Patients: Results of an Observational Pharmacokinetic Pilot Study. Pharmaceutics 2022;14:1304. [PMID: 35745876 DOI: 10.3390/pharmaceutics14061304] [Reference Citation Analysis]
76 Lenain R, Maanaoui M, Hamroun A, Larrue R, Van Der Hauwaert C, Gibier JB, Gnemmi V, Gomis S, Labalette M, Broly F, Hennart B, Pottier N, Hazzan M, Cauffiez C, Glowacki F. Impact of Tacrolimus Daily Dose Limitation in Renal Transplant Recipients Expressing CYP3A5: A Retrospective Study. J Pers Med 2021;11:1002. [PMID: 34683143 DOI: 10.3390/jpm11101002] [Reference Citation Analysis]
77 Quintairos L, Colom H, Millán O, Fortuna V, Espinosa C, Guirado L, Budde K, Sommerer C, Lizana A, López-Púa Y, Brunet M. Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients. PLoS One 2021;16:e0245880. [PMID: 33481955 DOI: 10.1371/journal.pone.0245880] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Kim EJ, Kim SJ, Huh KH, Kim BS, Kim MS, Kim SI, Kim YS, Lee J. Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk. Sci Rep 2021;11:12114. [PMID: 34108576 DOI: 10.1038/s41598-021-91630-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Staatz CE, Isbel NM, Bergmann TK, Jespersen B, Buus NH. Editorial: Therapeutic Drug Monitoring in Solid Organ Transplantation. Front Pharmacol 2021;12:815117. [PMID: 34955866 DOI: 10.3389/fphar.2021.815117] [Reference Citation Analysis]
80 Fontova P, Colom H, Rigo-Bonnin R, van Merendonk LN, Vidal-Alabró A, Montero N, Melilli E, Meneghini M, Manonelles A, Cruzado JM, Torras J, Grinyó JM, Bestard O, Lloberas N. Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation. Front Pharmacol 2021;12:636048. [PMID: 33815118 DOI: 10.3389/fphar.2021.636048] [Reference Citation Analysis]
81 Kou K, Sun X, Li M, Li T, Hu Y, Li S, Lv G. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes. J Clin Pharm Ther 2021. [PMID: 34708436 DOI: 10.1111/jcpt.13533] [Reference Citation Analysis]
82 Francke MI, Andrews LM, Lan Le H, van de Velde D, Dieterich M, Udomkarnjananun S, Clahsen-van Groningen MC, Baan CC, van Gelder T, de Winter BCM, Hesselink DA. Monitoring intracellular tacrolimus concentrations and its relationship with rejection in the early phase after renal transplantation. Clin Biochem 2021:S0009-9120(21)00319-2. [PMID: 34890583 DOI: 10.1016/j.clinbiochem.2021.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Veenhof H, Schouw HM, Besouw MTP, Touw DJ, Gracchi V. Flucloxacillin decreases tacrolimus blood trough levels: a single-center retrospective cohort study. Eur J Clin Pharmacol 2020;76:1667-73. [PMID: 32712713 DOI: 10.1007/s00228-020-02968-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Pasternak AL, Marshall VD, Gersch CL, Rae JM, Englesbe M, Park JM. Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus. Pharmgenomics Pers Med 2021;14:319-26. [PMID: 33746516 DOI: 10.2147/PGPM.S285444] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Cheng F, Li Q, Wang J, Hu M, Zeng F, Wang Z, Zhang Y. Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients. Pharmgenomics Pers Med 2021;14:1463-74. [PMID: 34824543 DOI: 10.2147/PGPM.S337947] [Reference Citation Analysis]
86 Miyagi SJ, Lam E, Tang Girdwood S. Partnering with Clinical Pharmacologists to Improve Medication Use in Children. J Pediatr 2020;227:5-8. [PMID: 33228913 DOI: 10.1016/j.jpeds.2020.03.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Zwart TC, Moes DJAR, van der Boog PJM, van Erp NP, de Fijter JW, Guchelaar HJ, Keizer RJ, Ter Heine R. Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients. Clin Pharmacokinet 2021;60:191-203. [PMID: 32720301 DOI: 10.1007/s40262-020-00925-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Déri M, Szakál-Tóth Z, Fekete F, Mangó K, Incze E, Minus A, Merkely B, Sax B, Monostory K. CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients. Sci Rep 2021;11:21389. [PMID: 34725418 DOI: 10.1038/s41598-021-00942-y] [Reference Citation Analysis]
89 Taber DJ, Hirsch J, Keys A, Su Z, McGillicuddy JW. Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients. Ther Drug Monit 2021;43:401-7. [PMID: 33560095 DOI: 10.1097/FTD.0000000000000863] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Grabarek BO, Kasela T, Adwent I, Zawidlak-Węgrzyńska B, Brus R. Evaluation of the Influence of Adalimumab on the Expression Profile of Leptin-Related Genes and Proteins in Keratinocytes Treated with Lipopolysaccharide A. Int J Mol Sci 2021;22:1595. [PMID: 33562571 DOI: 10.3390/ijms22041595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 De Gregori S, De Silvestri A, Cattadori B, Rapagnani A, Albertini R, Novello E, Concardi M, Arbustini E, Pellegrini C. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy in Heart Transplantation: New Strategies and Preliminary Results in Endomyocardial Biopsies. Pharmaceutics 2022;14:1247. [PMID: 35745819 DOI: 10.3390/pharmaceutics14061247] [Reference Citation Analysis]
92 Zhang W, Matsukane R, Egashira N, Tsuchiya Y, Fu R, Yamamoto S, Hirota T, Ieiri I. Neuroprotective effects of ibudilast against tacrolimus induced neurotoxicity. Toxicology and Applied Pharmacology 2022. [DOI: 10.1016/j.taap.2022.116112] [Reference Citation Analysis]
93 Chen L, Yang Y, Wang X, Wang C, Lin W, Jiao Z, Wang Z. Wuzhi Capsule Dosage Affects Tacrolimus Elimination in Adult Kidney Transplant Recipients, as Determined by a Population Pharmacokinetics Analysis. Pharmgenomics Pers Med 2021;14:1093-106. [PMID: 34511980 DOI: 10.2147/PGPM.S321997] [Reference Citation Analysis]
94 Chen Z, Cheng X, Zhang L, Tang L, Fang Y, Chen H, Zhang L, Shen A. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients. Pharmacol Rep 2021. [PMID: 34089513 DOI: 10.1007/s43440-021-00288-2] [Reference Citation Analysis]
95 Zhang SF, Tang BH, An-Hua W, Du Y, Guan ZW, Li Y. Effect of drug combination on tacrolimus target dose in renal transplant patients with different CYP3A5 genotypes. Xenobiotica 2022;:1-33. [PMID: 35395919 DOI: 10.1080/00498254.2022.2064252] [Reference Citation Analysis]
96 Huang L, Assiri AA, Wen P, Zhang K, Fan J, Xing T, Liu Y, Zhang J, Wang Z, Su Z, Chen J, Xiao Y, Wang R, Na R, Yuan L, Liu D, Xia J, Zhong L, Liu W, Guo W, Overholser BR, Peng Z. The CYP3A5 genotypes of both liver transplant recipients and donors influence the time-dependent recovery of tacrolimus clearance during the early stage following transplantation. Clin Transl Med 2021;11:e542. [PMID: 34709766 DOI: 10.1002/ctm2.542] [Reference Citation Analysis]
97 Cremers S, Lyashchenko A, Rai AJ, Hayden J, Dasgupta A, Tsapepas D, Mohan S. Challenged comparison of tacrolimus assays. Scandinavian Journal of Clinical and Laboratory Investigation. [DOI: 10.1080/00365513.2022.2056858] [Reference Citation Analysis]
98 Djabarouti S, Mora P, Lahouati M, Gigan M, d’Houdain N, Sourisseau B, Chambord J, Xuereb F. Intérêt des dosages pharmacologiques d’immunosuppresseurs et immunomodulateurs dans la prise en charge des maladies autoimmunes. La Revue de Médecine Interne 2022. [DOI: 10.1016/j.revmed.2022.03.343] [Reference Citation Analysis]
99 Sallustio BC. Monitoring Intra-cellular Tacrolimus Concentrations in Solid Organ Transplantation: Use of Peripheral Blood Mononuclear Cells and Graft Biopsy Tissue. Front Pharmacol 2021;12:733285. [PMID: 34764868 DOI: 10.3389/fphar.2021.733285] [Reference Citation Analysis]
100 Du WW, Wang XX, Zhang D, Chen WQ, Zhang XL, Li PM. Retrospective analysis on incidence and risk factors of early onset acute kidney injury after lung transplantation and its association with mortality. Ren Fail 2021;43:535-42. [PMID: 33736580 DOI: 10.1080/0886022X.2021.1883652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]